Skip to main content

Table 1 Associations of emmprin with clinical factors in endometrial cancer patients

From: Role of emmprin in endometrial cancer

  

Emmprin

 

   Variable

Numbers

mean ± SE

p-value

Age (years)

  

0.445

<60

80

1.38 ± 0.70

 

≥60

54

1.48 ± 0.84

 

FIGO stage

  

0.009*

I-II

85

1.30 ± 0.65

 

III-IV

49

1.61 ± 0.67

 

Histology

  

0.017*

Type I (G1 + G2)

106

1.34 ± 0.69

 

Type II (G3 + carcinosarcoma)

28

1.68 ± 0.54

 

Depth of myometrial invasion

  

0.001*

<1/2

87

1.28 ± 0.66

 

≥1/2

47

1.66 ± 0.63

 

Cervical involvement

  

0.001*

Negative

105

1.32 ± 0.67

 

Positive

29

1.75 ± 0.57

 

Lymph node metastasis

  

<0.001*

Negative

116

1.34 ± 0.67

 

Positive

18

1.89 ± 0.47

 

LVS involvement

  

<0.001*

Negative

90

1.27 ± 0.67

 

Positive

44

1.70 ± 0.59

 

Ovarian metastasis

  

0.127

Negative

119

1.38 ± 0.66

 

Positive

15

1.66 ± 0.72

 

Peritoneal cytology

  

0.031*

Negative

105

1.35 ± 0.67

 

Positive

29

1.65 ± 0.61

 
  1. *Mann–Whitney U-test; FIGO, International Federation of Gynecology and Obstetrics; LVS, lymph vascular space.